6:03 PM
 | 
Nov 04, 2013
 |  BC Extra  |  Clinical News

More data for two-dose regimen of GSK's HPV vaccine

Researchers at NIH's National Cancer Institute and colleagues reported data from the Phase III CVT trial in females aged 18-25 that they said raise the possibility that even a single dose of HPV vaccine Cervarix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will induce long-term protection against HPV infection. In the trial, a two-dose schedule of Cervarix administered at zero and six months led to HPV types 16 and 18 geometric mean...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >